Bioaffinity Technologies, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
A group of investment entities led by Michael Bigger reported a complete divestment of their beneficial ownership in bioAffinity Technologies, Inc. common stock, falling below the 5% threshold.
NASDAQ
Richard K. Crumly, along with ADAMAS LLC and BMUS PARTNERS LLC, has filed a Schedule 13G disclosing a collective beneficial ownership of 11.2% of bioAffinity Technologies, Inc.'s common stock.